USANA HEALTH SCIENCES, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
USANA HEALTH SCIENCES, INC. (USNA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.65 million for the 6-month period ending 2026-07-04, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-13
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-07-04 was $1.43M, a 38.34% decline year-over-year.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-04-04 was $214.00K, a 94.57% decline year-over-year.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-28 was $2.32M.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-29 was $3.94M.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2026 was $8.64M, a 30.65% decline from fiscal 2024.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $12.46M, a 118.69% increase from fiscal 2023.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $5.70M, a 1.03% increase from fiscal 2022.
- USANA HEALTH SCIENCES, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $5.64M, a 5.99% increase from fiscal 2022.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-07-04 | $1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.65M 10-Q · filed 2026-08-13 | |||
| 2026-04-04 | $214.00K 10-Q · filed 2026-05-12 | ||||
| 2026-01-03 | $8.64M 10-K · filed 2026-03-16 | ||||
| 2025-06-28 | $2.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.26M 10-Q · filed 2026-08-13 | |||
| 2025-03-29 | $3.94M 10-Q · filed 2026-05-12 | ||||
| 2024-12-28 | $12.46M 10-K · filed 2026-03-16 | ||||
| 2023-12-30 | $5.70M 10-K · filed 2026-03-16 | ||||
| 2022-12-31 | $5.64M 10-K · filed 2025-03-12 | ||||
| 2022-01-01 | $5.32M 10-K · filed 2024-02-27 | ||||
| 2021-01-02 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $6.63M 10-K · filed 2022-03-01 | |||
| 2020-09-26 | $3.77M 10-Q · filed 2020-11-03 | ||||
| 2019-12-28 | -$12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | $10.27M derived: sum of 2 quarters · filed 2021-03-02 | $12.96M derived: sum of 3 quarters · filed 2021-03-02 | $13.57M 10-K · filed 2021-03-02 | |
| 2019-09-28 | $22.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $25.26M derived: sum of 2 quarters · filed 2020-11-03 | $25.87M 10-Q · filed 2020-11-03 | $6.21M 10-Q · filed 2019-11-05 | |
| 2019-06-29 | $2.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $3.31M 10-Q · filed 2019-08-06 | |||
| 2019-03-30 | $615.00K 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |